Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
113
Recruiting, any sponsor type, condition "atrial fibrillation"
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting113
- Completed542
113 trials
Showing 1 to 25, recently updated first.
- Early Closure of Left Atrial Appendage for Patients With Atrial Fibrillation and Ischemic Stroke Despite Anticoagulation TherapyPivotal-lookingRecruiting
Insel Gruppe AG, University Hospital BernAcademic, hospital or other
NCT05976685 · 482 participants (planned) · Start May 1, 2024 · Primary completion Jan 1, 2028
Drug: DOAC · For: Ischemic Stroke; Atrial Fibrillation
Sites: Bruges, Belgium; Brussels, Belgium; Charleroi, Belgium · 35 sites in all
- A Study Of Stellate Ganglion Blockade With Liposomal Bupivacaine In Preventing Atrial Fibrillation After Isolated Coronary Artery Bypass Grafting SurgeryPivotal-lookingRecruiting
Mayo ClinicAcademic, hospital or other
NCT07570940 · 450 participants (planned) · Start Sep 29, 2026 · Primary completion Sep 2030
Drug: Liposomal bupivacaine; Placebo · For: Coronary Artery Disease; Atrial Fibrillation
Sites: Rochester, Minnesota
- Stroke and Systemic Embolism Prevention in Adult Participants With Atrial FibrillationPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07626411 · 15,364 participants (planned) · Start Aug 10, 2026 · Primary completion Sep 11, 2029
Drug: REGN7508; Apixaban and 1 more · For: Atrial Fibrillation (AF)
Sites: Alexander City, Alabama; Dothan, Alabama; Fairhope, Alabama · 84 sites in all
- BEACON-AA: Apixaban With or Without Clopidogrel in Stroke Patients With Atrial Fibrillation and Cerebral AtherosclerosisPivotal-lookingRecruiting
Yonsei UniversityAcademic, hospital or other
NCT07237308 · 586 participants (planned) · Start Jul 14, 2026 · Primary completion Jul 1, 2029
Drug: Apixaban; Clopidogrel · For: Stroke; Ischemic; Atrial Fibrillation and 2 more
Sites: Busan, South Korea; Chuncheon, South Korea; Daegu, South Korea · 21 sites in all
- Statin Therapy With Atorvastatin in Surgical Aortic Valve ReplacementPivotal-lookingRecruiting
Odense University HospitalAcademic, hospital or other
NCT05076019 · 266 participants (planned) · Start Feb 1, 2022 · Primary completion Dec 1, 2027
Drug: Atorvastatin 80mg; Placebo · For: Postoperative Atrial Fibrillation
Sites: Odense, Denmark
- Effect of Protocolized Magnesium Replacement on Mortality and Atrial Fibrillation in Critically Ill PatientsPivotal-lookingRecruiting
Scarborough General HospitalAcademic, hospital or other
NCT07173855 · 3,853 participants (planned) · Start Nov 25, 2025 · Primary completion Mar 1, 2027
Drug: Magnesium sulfate administration; Magnesium oxide and 1 more · For: Critical Illness
Sites: Ajax, Canada; Bowmanville, Canada; Oshawa, Canada · 6 sites in all
- Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is UnsuitablePivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07430956 · 2,628 participants (planned) · Start Apr 3, 2026 · Primary completion Mar 28, 2029
Drug: REGN7508; REGN9933 and 1 more · For: Atrial Fibrillation (AF)
Sites: Dothan, Alabama; Glendale, Arizona; Little Rock, Arkansas · 45 sites in all
- Monotherapy With P2Y12 Inhibitors in Patients With Atrial fIbrillation Undergoing Drug-eluting Stent ImplantationPivotal-lookingRecruiting
Insel Gruppe AG, University Hospital BernAcademic, hospital or other
NCT05955365 · 3,010 participants (planned) · Start Dec 18, 2023 · Primary completion Dec 31, 2027
Drug: P2Y12 inhibitor; Aspirin and 1 more · For: Percutaneous Coronary Intervention (PCI); Atrial Fibrillation (AF); Oral Anticoagulation and 1 more
Sites: Hasselt, Belgium; Nîmes, France; Frankfurt am Main, Germany · 18 sites in all
- ReVeRA-301: Etripamil in Atrial Fibrillation Phase 3Pivotal-lookingRecruiting
Milestone Pharmaceuticals Inc.Academic, hospital or other
NCT06716021 · 750 participants (planned) · Start Aug 20, 2026 · Primary completion Dec 2028
Drug: Placebo; Etripamil · For: Atrial Fibrillation
Sites: Vista, California; West Hills, California; Littleton, Colorado · 23 sites in all
- MAGNEsium With meToprolol for Rate Control In Atrial FibrillationPivotal-lookingRecruiting
Wake Forest University Health SciencesAcademic, hospital or other
NCT07632157 · 196 participants (planned) · Start Nov 10, 2026 · Primary completion Dec 2028
Drug: Magnesium Sulfate 2g; Magnesium Sulfate 4g and 1 more · For: Atrial Flutter With Rapid Ventricular Response
Sites: Oak Lawn, Illinois
- Safety in Adult Participants With Atrial Fibrillation Who Are Treated With AnticoagulationPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07175428 · 1,200 participants (planned) · Start Oct 20, 2025 · Primary completion Feb 9, 2027
Drug: REGN7508; REGN9933 and 1 more · For: Atrial Fibrillation (AF)
Sites: Dothan, Alabama; Fairhope, Alabama; Covina, California · 91 sites in all
- Thrombolysis in Factor Xa-inhibitors TrialPivotal-lookingRecruiting
Guri HagbergAcademic, hospital or other
NCT06878066 · 300 participants (planned) · Start Mar 14, 2025 · Primary completion Dec 31, 2028
Drug: thrombolysis therapy · For: Stroke; Stroke (in Patients With Atrial Fibrillation); Ischemic Stroke and 6 more
Sites: Aalborg, Denmark; Aarhus, Denmark; Baerum, Norway · 21 sites in all
- The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial FibrillationPivotal-lookingRecruiting
Johns Hopkins UniversityAcademic, hospital or other
NCT05836987 · 5,350 participants (planned) · Start Jul 13, 2023 · Primary completion Jul 31, 2029
Drug: Continuous DOAC therapy · For: Atrial Fibrillation
Sites: Phoenix, Arizona; Los Angeles, California; Sacramento, California · 93 sites in all
- A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial FibrillationPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07217067 · 165 participants (planned) · Start Oct 28, 2025 · Primary completion Sep 9, 2027
Drug: PKN605 · For: Atrial Fibrillation
Sites: Tupelo, Mississippi; Camden, New Jersey; New York, New York · 40 sites in all
East Sussex Healthcare NHS TrustAcademic, hospital or other
NCT07900685 · 60 participants (planned) · Start Oct 19, 2026 · Primary completion Apr 1, 2028
Drug: Deep sedation with midazolam and fentanyl or midazolam and remifentanil; Sedation with midazolam and fentanyl · For: Atrial Fibrillation (AF)
Sites: Eastbourne, United Kingdom
- Conscious Sedation Versus General Anesthesia for Pulsed Field Ablation in Paroxysmal Atrial FibrillationPivotal-lookingRecruiting
China National Center for Cardiovascular DiseasesGovernment (non-federal)
NCT07877519 · 390 participants (planned) · Start Jun 1, 2026 · Primary completion Jun 2028
Drug: Compound methoxyphenamine capsules; Salbutamol and 7 more · For: Paroxysmal Atrial Fibrillation
Sites: Beijing, China
Centre Hospitalier Universitaire DijonAcademic, hospital or other
NCT07648329 · 150 participants (planned) · Start Oct 20, 2026 · Primary completion Oct 2029
Drug: blood draw · For: Atrial Fibrillation (AF); Cardiac Arrhythmia; Atrial Fibrillation Ablation and 2 more
Sites: Dijon, France
- Can Patients With Atrial Fibrillation Safely Discontinue Anticoagulant Therapy After Cardiac Surgery? (ATLAAC)Pivotal-lookingRecruiting
Odense University HospitalAcademic, hospital or other
NCT06401616 · 1,220 participants (planned) · Start May 21, 2024 · Primary completion Mar 1, 2028
Drug: OAC will be discontinued for the duration of the trial · For: Atrial Fibrillation; Left Atrial Appendage Absent; Anticoagulant Adverse Reaction
Sites: Copenhagen, Denmark; Gentofte Municipality, Denmark; Herning, Denmark · 6 sites in all
- Flecainide Safety in Patients With Coronary Artery Disease and Atrial FibrillationPivotal-lookingRecruiting
Universitaire Ziekenhuizen KU LeuvenAcademic, hospital or other
NCT07405671 · 988 participants (planned) · Start Sep 2026 · Primary completion Dec 2029
Drug: flecainide; Sotalol or Amiodarone · For: Atrial Fibrillation (AF); Coronary Artery Disease
Sites: Aalst, Belgium; Bonheiden, Belgium; Bruges, Belgium · 14 sites in all
- A Study to Test How Well BAY 3670549 Works and How Safe it is in Patients With Atrial FibrillationPivotal-lookingRecruiting
BayerBayer (BAYRY)
NCT07625215 · 360 participants (planned) · Start Sep 1, 2026 · Primary completion May 16, 2030
Drug: BAY 3670549 · For: Atrial Fibrillation
Sites: San Francisco, California; Aurora, Colorado; Boston, Massachusetts · 30 sites in all
Nova Scotia Health AuthorityAcademic, hospital or other
NCT07272902 · 84 participants (planned) · Start Jan 1, 2026 · Primary completion Oct 2027
Drug: Rate Control Medications (beta-blockers, calcium channel blockers, digoxin) · For: Atrial Fibrillation (AF); Heart Failure With Mildly Reduced Ejection Fraction; Heart Failure With Preserved Ejection Fraction (HFPEF) and 2 more
Sites: Halifax, Canada; Hamilton, Canada; London, Canada · 4 sites in all
Fundación EPICAcademic, hospital or other
NCT06620757 · 234 participants (planned) · Start Oct 10, 2024 · Primary completion Oct 10, 2027
Drug: Single antiplatelet therapy (SAPT) · For: Atrial Fibrillation
Sites: A Coruña, Spain; Aravaca, Spain; Barcelona, Spain · 22 sites in all
- Catheter Ablation vs Conservative Care in Elderly Patients With Atrial FibrillationPivotal-lookingRecruiting
Karolinska University HospitalAcademic, hospital or other
NCT07424690 · 282 participants (planned) · Start Oct 5, 2026 · Primary completion Dec 15, 2031
Drug: Optimized Medical Therapy for Atrial Fibrillation · For: Atrial Fibrillation (AF); Atrial Fibrillation Ablation; Elderly
Sites: Linköping, Sweden; Stockholm, Sweden
- Optimal Anti-Thrombotic Management Following Percutaneous Left Atrial Appendage OcclusionPivotal-lookingRecruiting
Texas Cardiac Arrhythmia Research FoundationAcademic, hospital or other
NCT07840365 · 234 participants (planned) · Start Sep 1, 2026 · Primary completion Dec 15, 2028
Drug: Half-Dose of novel OAC; Low-dose ASA · For: Atrial Fibrillation (AF)
Sites: Austin, Texas
- COmparison of Bleeding Risk Between Rivaroxaban and Apixaban in Patients With Atrial FibrillationPivotal-lookingRecruiting
Ottawa Hospital Research InstituteAcademic, hospital or other
NCT04642430 · 3,018 participants (planned) · Start Jul 6, 2021 · Primary completion Dec 31, 2027
Drug: Apixaban; Rivaroxaban · For: Atrial Fibrillation
Sites: Victoria, Canada; Halifax, Canada; Kingston, Canada · 8 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.